{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:11:30Z","timestamp":1792228290052,"version":"4.4.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00415-025-13093-1","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T06:22:45Z","timestamp":1747290165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1255-9701","authenticated-orcid":false,"given":"Mark S.","family":"Freedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9731-4169","authenticated-orcid":false,"given":"Ahmed","family":"Abdelhak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4337-4144","authenticated-orcid":false,"given":"Mohit K.","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-9922","authenticated-orcid":false,"given":"Sharmilee","family":"Gnanapavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1691-8428","authenticated-orcid":false,"given":"Salman","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5697-1411","authenticated-orcid":false,"given":"Sheshank","family":"Madiraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6378-0070","authenticated-orcid":false,"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"13093_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G (2019) Multiple sclerosis\u2014a review. Eur J Neurol 26:27\u201340. https:\/\/doi.org\/10.1111\/ene.13819","journal-title":"Eur J Neurol"},{"key":"13093_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/s0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502\u20131517. https:\/\/doi.org\/10.1016\/s0140-6736(08)61620-7","journal-title":"Lancet"},{"key":"13093_CR3","unstructured":"MS International Federation (2022) Atlas of MS 2022. https:\/\/www.atlasofms.org\/map\/united-kingdom\/epidemiology\/number-of-people-with-ms. Accessed 17 October 2024."},{"key":"13093_CR4","unstructured":"National Multiple Sclerosis Society (2019) New study doubles the previous estimate in the U.S. https:\/\/www.nationalmssociety.org\/news-and-magazine\/momentum-magazine\/research-and-science\/1-million-live-with-ms. Accessed 29 June 2024."},{"key":"13093_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/s1474-4422(24)00038-3","volume":"23","author":"GBD 2021 Nervous System Disorders Collaborators","year":"2024","unstructured":"GBD 2021 Nervous System Disorders Collaborators (2024) Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 23:344\u2013381. https:\/\/doi.org\/10.1016\/s1474-4422(24)00038-3","journal-title":"Lancet Neurol"},{"key":"13093_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104019","volume":"66","author":"J Li","year":"2022","unstructured":"Li J, Zakeri M, Hutton GJ, Aparasu RR (2022) Health-related quality of life of patients with multiple sclerosis: analysis of ten years of national data. Mult Scler Relat Disord 66:104019. https:\/\/doi.org\/10.1016\/j.msard.2022.104019","journal-title":"Mult Scler Relat Disord"},{"key":"13093_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1471-2377-12-94","volume":"12","author":"J Pike","year":"2012","unstructured":"Pike J, Jones E, Rajagopalan K, Piercy J, Anderson P (2012) Social and economic burden of walking and mobility problems in multiple sclerosis. BMC Neurol 12:94. https:\/\/doi.org\/10.1186\/1471-2377-12-94","journal-title":"BMC Neurol"},{"key":"13093_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40273-021-01032-7","volume":"39","author":"J Dahham","year":"2021","unstructured":"Dahham J, Rizk R, Kremer I, Evers S, Hiligsmann M (2021) Economic burden of multiple sclerosis in low- and middle-income countries: a systematic review. Pharmacoeconomics 39:789\u2013807. https:\/\/doi.org\/10.1007\/s40273-021-01032-7","journal-title":"Pharmacoeconomics"},{"key":"13093_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1212\/wnl.0000000000003542","volume":"88","author":"MA Rocca","year":"2017","unstructured":"Rocca MA, Battaglini M, Benedict RHB, De Stefano N, Geurts JJG, Henry RG, Horsfield MA, Jenkinson M, Pagani E, Filippi M (2017) Brain MRI atrophy quantification in MS: from methods to clinical application. Neurology 88:403\u2013413. https:\/\/doi.org\/10.1212\/wnl.0000000000003542","journal-title":"Neurology"},{"key":"13093_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/bmj.38771.583796.7c","volume":"332","author":"P Whiting","year":"2006","unstructured":"Whiting P, Harbord R, Main C, Deeks JJ, Filippini G, Egger M, Sterne JAC (2006) Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. BMJ 332:875\u2013884. https:\/\/doi.org\/10.1136\/bmj.38771.583796.7c","journal-title":"BMJ"},{"key":"13093_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14:577\u2013589. https:\/\/doi.org\/10.1038\/s41582-018-0058-z","journal-title":"Nat Rev Neurol"},{"key":"13093_CR12","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1007\/s00018-004-4268-8","volume":"61","author":"Q Liu","year":"2004","unstructured":"Liu Q, Xie F, Siedlak SL, Nunomura A, Honda K, Moreira PI, Zhua X, Smith MA, Perry G (2004) Neurofilament proteins in neurodegenerative diseases. Cell Mol Life Sci 61:3057\u20133075. https:\/\/doi.org\/10.1007\/s00018-004-4268-8","journal-title":"Cell Mol Life Sci"},{"issue":"104970","key":"13093_CR13","doi-asserted-by":"publisher","first-page":"104970","DOI":"10.1016\/j.ebiom.2024.104970","volume":"101","author":"MS Freedman","year":"2024","unstructured":"Freedman MS, Gnanapavan S, Booth RA, Calabresi PA, Khalil M, Kuhle J, Lycke J, Olsson T, Consortium of Multiple Sclerosis Centers (2024) Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. Ebiomedicine 101(104970):104970. https:\/\/doi.org\/10.1016\/j.ebiom.2024.104970","journal-title":"Ebiomedicine"},{"key":"13093_CR14","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Sch\u00e4delin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J, Swiss Multiple Sclerosis Cohort Study Group (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81:857\u2013870. https:\/\/doi.org\/10.1002\/ana.24954","journal-title":"Ann Neurol"},{"key":"13093_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jamaneurol.2023.3997","volume":"80","author":"A Abdelhak","year":"2023","unstructured":"Abdelhak A, Benkert P, Schaedelin S, Boscardin WJ, Cordano C, Oechtering J, Ananth K, Granziera C, Melie-Garcia L, Montes SC, Beaudry-Richard A, Achtnichts L, Oertel FC, Lalive PH, Leppert D, M\u00fcller S, Henry RG, Pot C, Matthias A, Salmen A, Oksenberg JR, Disanto G, Zecca C, D\u2019Souza M, Du Pasquier R, Bridel C, Gobbi C, Kappos L, Hauser SL, Cree BAC, Kuhle J, Green AJ, UCSF, MS EPIC, and the SMSC Study Teams (2023) Neurofilament light chain elevation and disability progression in multiple sclerosis. JAMA Neurol 80:1317\u20131325. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3997","journal-title":"JAMA Neurol"},{"key":"13093_CR16","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","volume":"141","author":"C Barro","year":"2018","unstructured":"Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera C, Yaldizli \u00d6, Michalak Z, Wuerfel J, Kappos L, Parmar K, Kuhle J (2018) Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141:2382\u20132391. https:\/\/doi.org\/10.1093\/brain\/awy154","journal-title":"Brain"},{"key":"13093_CR17","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.1212\/wnl.0000000000200778","volume":"99","author":"ES Sotirchos","year":"2022","unstructured":"Sotirchos ES, Vasileiou ES, Filippatou AG, Fitzgerald KC, Smith MD, Lord HN, Kalaitzidis G, Lambe J, Duval A, Prince JL, Mowry EM, Saidha S, Calabresi PA (2022) Association of serum neurofilament light chain with inner retinal layer thinning in multiple sclerosis. Neurology 99:e688\u2013e697. https:\/\/doi.org\/10.1212\/wnl.0000000000200778","journal-title":"Neurology"},{"key":"13093_CR18","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1212\/wnl.0000000000007767","volume":"93","author":"MM Mielke","year":"2019","unstructured":"Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, Machulda MM, Kremers WK, Knopman DS, Jack C Jr, Petersen RC, Kern S (2019) Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology 93:e252\u2013e260. https:\/\/doi.org\/10.1212\/wnl.0000000000007767","journal-title":"Neurology"},{"key":"13093_CR19","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius \u00c5, Liman V, Norgren N, Blennow K, Zetterberg H (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54:1655\u20131661. https:\/\/doi.org\/10.1515\/cclm-2015-1195","journal-title":"Clin Chem Lab Med"},{"key":"13093_CR20","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1177\/13524585241277044","volume":"30","author":"ZYGJ van Lierop","year":"2024","unstructured":"van Lierop ZYGJ, Wessels MHJ, Lekranty WML, Moraal B, Hof SN, Hogenboom L, de Jong BA, Meijs N, Mensing LA, van Oosten BW, Sol N, van Kempen ZLE, Vermunt L, Willems MJ, Strijbis EMM, Uitdehaag BMJ, Killestein J, Teunissen CE (2024) Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic. Mult Scler 30:1620\u20131629. https:\/\/doi.org\/10.1177\/13524585241277044","journal-title":"Mult Scler"},{"key":"13093_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40120-022-00427-8","volume":"12","author":"A Bar-Or","year":"2023","unstructured":"Bar-Or A, Montalban X, Hu X, Kropshofer H, Kukkaro P, Coello N, Ludwig I, Willi R, Zalesak M, Ramanathan K, Kieseier BC, H\u00e4ring DA, Bagger M, Fox E (2023) Serum neurofilament light trajectories and their relation to subclinical radiological disease activity in relapsing multiple sclerosis patients in the APLIOS trial. Neurol Ther 12:303\u2013317. https:\/\/doi.org\/10.1007\/s40120-022-00427-8","journal-title":"Neurol Ther"},{"key":"13093_CR22","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/wnl.0000000000004683","volume":"89","author":"L Novakova","year":"2017","unstructured":"Novakova L, Zetterberg H, Sundstr\u00f6m P, Axelsson M, Khademi M, Gunnarsson M, Malmestr\u00f6m C, Svenningsson A, Olsson T, Piehl F, Blennow K, Lycke J (2017) Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology 89:2230\u20132237. https:\/\/doi.org\/10.1212\/wnl.0000000000004683","journal-title":"Neurology"},{"key":"13093_CR23","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1177\/1352458517715132","volume":"24","author":"F Piehl","year":"2018","unstructured":"Piehl F, Kockum I, Khademi M, Blennow K, Lycke J, Zetterberg H, Olsson T (2018) Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler 24:1046\u20131054. https:\/\/doi.org\/10.1177\/1352458517715132","journal-title":"Mult Scler"},{"key":"13093_CR24","unstructured":"NICE (2022) NICE health technology evaluations: the manual. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation. Accessed 05 October 2023."},{"key":"13093_CR25","unstructured":"CRD (2009) Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf. Accessed 05 October 2023."},{"key":"13093_CR26","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) (2024) Cochrane Handbook for Systematic Reviews of Interventions version 6.5. https:\/\/training.cochrane.org\/handbook\/current. Accessed 17 October 2024."},{"key":"13093_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"13093_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"13093_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun Health 52:377\u2013384. https:\/\/doi.org\/10.1136\/jech.52.6.377","journal-title":"J Epidemiol Commun Health"},{"key":"13093_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI McDonald","year":"2001","unstructured":"McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121\u2013127. https:\/\/doi.org\/10.1002\/ana.1032","journal-title":"Ann Neurol"},{"key":"13093_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O\u2019Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366","journal-title":"Ann Neurol"},{"key":"13093_CR32","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O\u2019Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria.\u201d Ann Neurol 58:840\u2013846. https:\/\/doi.org\/10.1002\/ana.20703","journal-title":"Ann Neurol"},{"key":"13093_CR33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/s1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintor\u00e9 M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173. https:\/\/doi.org\/10.1016\/s1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"13093_CR34","unstructured":"Montalban X (2024) 2024 revisions of the McDonald criteria. In: ECTRIMS Congress; September 18\u201320, 2024; Copenhagen, Denmark. Lecture 1. https:\/\/ectrims.eu\/app\/uploads\/2024\/10\/2024_McDonald_Criteria_ECTRIMS.XM_.FINAL_.pptx. Accessed 04 November 2024."},{"key":"13093_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104458","volume":"70","author":"HH Chow","year":"2023","unstructured":"Chow HH, Talbot J, Lundell H, Marstrand L, Madsen CG, S\u00f8ndergaard HB, Hansen MB, S\u00f8rensen PS, Siebner HR, Sellebjerg F (2023) Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study. Mult Scler Relat Disord 70:104458. https:\/\/doi.org\/10.1016\/j.msard.2022.104458","journal-title":"Mult Scler Relat Disord"},{"key":"13093_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/13524585231169437","volume":"29","author":"J Kuhle","year":"2023","unstructured":"Kuhle J, Kappos L, Montalban X, Benkert P, Li Y, Thangavelu K, Hyvert Y, Tomic D (2023) Neurofilament light chain levels and disease activity during long-term treatment of relapsing multiple sclerosis with the bruton\u2019s tyrosine kinase inhibitor evobrutinib. Mult Scler 29:31\u201332. https:\/\/doi.org\/10.1177\/13524585231169437","journal-title":"Mult Scler"},{"key":"13093_CR37","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/jnnp-2022-329020","volume":"93","author":"M Comabella","year":"2022","unstructured":"Comabella M, Sastre-Garriga J, Carbonell-Mirabent P, Fissolo N, Tur C, Malhotra S, Pareto D, Aymerich FX, R\u00edo J, Rovira A, Tintor\u00e9 M, Montalban X (2022) Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 93:732\u2013740. https:\/\/doi.org\/10.1136\/jnnp-2022-329020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13093_CR38","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3390\/brainsci12121595","volume":"12","author":"D Paolicelli","year":"2022","unstructured":"Paolicelli D, Ruggieri M, Manni A, Gargano CD, Carleo G, Palazzo C, Iaffaldano A, Bollo L, Guerra T, Saracino A, Frigeri A, Iaffaldano P, Trojano M (2022) Real-life experience of the effects of cladribine tablets on lymphocyte subsets and serum neurofilament light chain levels in relapsing multiple sclerosis patients. Brain Sci 12:1595. https:\/\/doi.org\/10.3390\/brainsci12121595","journal-title":"Brain Sci"},{"key":"13093_CR39","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1177\/1352458519885613","volume":"26","author":"J Kuhle","year":"2020","unstructured":"Kuhle J, Plavina T, Barro C, Disanto G, Sangurdekar D, Singh CM, de Moor C, Engle B, Kieseier BC, Fisher E, Kappos L, Rudick RA, Goyal J (2020) Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. Mult Scler 26:1691\u20131699. https:\/\/doi.org\/10.1177\/1352458519885613","journal-title":"Mult Scler"},{"key":"13093_CR40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/acn3.51704","volume":"10","author":"ES Sotirchos","year":"2023","unstructured":"Sotirchos ES, Fitzgerald KC, Singh CM, Smith MD, Reyes-Mantilla M, Hersh CM, Hyland MH, Canissario R, Simmons SB, Arrambide G, Montalban X, Comabella M, Naismith RT, Qiao M, Krupp LB, Nicholas JA, Akg\u00fcn K, Ziemssen T, Rudick R, Fisher E, Bermel RA, Mowry EM, Calabresi PA (2023) Associations of sNfL with clinico-radiological measures in a large MS population. Ann Clin Transl Neur 10:84\u201397. https:\/\/doi.org\/10.1002\/acn3.51704","journal-title":"Ann Clin Transl Neur"},{"key":"13093_CR41","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/wnl.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, H\u00e4ring DA, Kundu U, Meinert R, Barro C, Dahlke F, Tomic D, Leppert D, Kappos L (2019) Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92:e1007\u2013e1015. https:\/\/doi.org\/10.1212\/wnl.0000000000007032","journal-title":"Neurology"},{"key":"13093_CR42","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000856","volume":"7","author":"DA H\u00e4ring","year":"2020","unstructured":"H\u00e4ring DA, Kropshofer H, Kappos L, Cohen JA, Shah A, Meinert R, Leppert D, Tomic D, Kuhle J (2020) Long-term prognostic value of longitudinal measurements of blood neurofilament levels. Neurol Neuroimmunol Neuroinflamm 7:e856. https:\/\/doi.org\/10.1212\/nxi.0000000000000856","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13093_CR43","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1177\/13524585231195346","volume":"29","author":"SL Hauser","year":"2023","unstructured":"Hauser SL, Zielman R, Gupta AD, Xi J, Stoneman D, Karlsson G, Robertson D, Cohen JA, Kappos L (2023) Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension. Mult Scler 29:1452\u20131464. https:\/\/doi.org\/10.1177\/13524585231195346","journal-title":"Mult Scler"},{"key":"13093_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104662","volume":"93","author":"A Bar-Or","year":"2023","unstructured":"Bar-Or A, Thanei GA, Harp C, Bernasconi C, Bonati U, Cross AH, Fischer S, Gaetano L, Hauser SL, Hendricks R, Kappos L, Kuhle J, Leppert D, Model F, Sauter A, Koendgen H, Jia X, Herman AE (2023) Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine 93:104662. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104662","journal-title":"EBioMedicine"},{"key":"13093_CR45","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1177\/13524585221097296","volume":"28","author":"S Brune","year":"2022","unstructured":"Brune S, H\u00f8gest\u00f8l EA, de Rodez Benavent SA, Berg-Hansen P, Beyer MK, Leikfoss IS, Bos SD, Sowa P, Brunborg C, Andorra M, Valdeolivas IP, Asseyer S, Brandt A, Chien C, Scheel M, Blennow K, Zetterberg H, Kerlero de Rosbo N, Paul F, Uccelli A, Villoslada P, Berge T, Harbo HF (2022) Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. Mult Scler 28:1859\u20131870. https:\/\/doi.org\/10.1177\/13524585221097296","journal-title":"Mult Scler"},{"key":"13093_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.632749","volume":"12","author":"A Dal-Bianco","year":"2021","unstructured":"Dal-Bianco A, Schranzer R, Grabner G, Lanzinger M, Kolbrink S, Pusswald G, Altmann P, Ponleitner M, Weber M, Kornek B, Zebenholzer K, Schmied C, Berger T, Lassmann H, Trattnig S, Hametner S, Leutmezer F, Rommer P (2021) Iron rims in patients with multiple sclerosis as neurodegenerative marker? A 7-Tesla magnetic resonance study. Front Neurol 12:632749. https:\/\/doi.org\/10.3389\/fneur.2021.632749","journal-title":"Front Neurol"},{"key":"13093_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103446","volume":"58","author":"R Zhou","year":"2022","unstructured":"Zhou R, Li H, Yang H, Jiang F, Cai H, Li J, Chen S, Fang L, Yin J, Zeng Q (2022) Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis. Mult Scler Relat Disord 58:103446. https:\/\/doi.org\/10.1016\/j.msard.2021.103446","journal-title":"Mult Scler Relat Disord"},{"key":"13093_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577541","volume":"354","author":"J Giarraputo","year":"2021","unstructured":"Giarraputo J, Giamberardino S, Arvai S, Maichle S, Eckstein C, Newby LK, Gregory S (2021) Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis. J Neuroimmunol 354:577541. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577541","journal-title":"J Neuroimmunol"},{"key":"13093_CR49","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1177\/1352458519881428","volume":"26","author":"D Jakimovski","year":"2020","unstructured":"Jakimovski D, Zivadinov R, Ramanthan M, Hagemeier J, Weinstock-Guttman B, Tomic D, Kropshofer H, Fuchs TA, Barro C, Leppert D, Yaldizli \u00d6, Kuhle J, Benedict RHB (2020) Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: a longitudinal retrospective 5-year study. Mult Scler 26:1670\u20131681. https:\/\/doi.org\/10.1177\/1352458519881428","journal-title":"Mult Scler"},{"key":"13093_CR50","doi-asserted-by":"publisher","first-page":"205521732311694","DOI":"10.1177\/20552173231169463","volume":"9","author":"G Cutter","year":"2023","unstructured":"Cutter G, Rudick RA, de Moor C, Singh CM, Fisher E, Koster T, Lublin FD, Wolinsky JS, McFarland H, Jacobson S, Naylor ML (2023) Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: a post hoc analysis of the randomized CombiRx trial. Mult Scler J Exp Transl Clin 9:20552173231169464. https:\/\/doi.org\/10.1177\/20552173231169463","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"13093_CR51","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/s1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli \u00d6, Maceski A, Oechtering J, Achtnichts L, Conen D, Derfuss T, Lalive PH, Mueller C, M\u00fcller S, Naegelin Y, Oksenberg JR, Pot C, Salmen A, Willemse E, Kockum I, Blennow K, Zetterberg H, Gobbi C, Kappos L, Wiendl H, Berger K, Sormani MP, Granziera C, Piehl F, Leppert D, Kuhle J, NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group (2022) Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 21:246\u2013257. https:\/\/doi.org\/10.1016\/s1474-4422(22)00009-6","journal-title":"Lancet Neurol"},{"key":"13093_CR52","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/ene.15465","volume":"29","author":"J Kuhle","year":"2022","unstructured":"Kuhle J, Kappos L, Montalban X, Li Y, Thangavelu K, Hyvert Y, Tomic D (2022) Evobrutinib reduces relapses and MRI outcomes in MS: association with baseline serum neurofilament light chain levels. Eur J Neurol 29:290\u2013291. https:\/\/doi.org\/10.1111\/ene.15465","journal-title":"Eur J Neurol"},{"key":"13093_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117079","volume":"417","author":"V Anderson","year":"2020","unstructured":"Anderson V, Bentley E, Loveless S, Bianchi L, Harding KE, Wynford-Thomas RA, Joseph F, Giovannoni G, Gnanapavan S, Robertson NP, Marta M, Tallantyre EC (2020) Serum neurofilament-light concentration and real-world outcome in MS. J Neurol Sci 417:117079. https:\/\/doi.org\/10.1016\/j.jns.2020.117079","journal-title":"J Neurol Sci"},{"key":"13093_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.852563","volume":"13","author":"T Ziemssen","year":"2022","unstructured":"Ziemssen T, Arnold DL, Alvarez E, Cross AH, Willi R, Li B, Kukkaro P, Kropshofer H, Ramanathan K, Merschhemke M, Kieseier B, Su W, H\u00e4ring DA, Hauser SL, Kappos L, Kuhle J (2022) Prognostic value of serum neurofilament light chain for disease activity and worsening in patients with relapsing multiple sclerosis: results from the phase 3 ASCLEPIOS I and II trials. Front Immunol 13:852563. https:\/\/doi.org\/10.3389\/fimmu.2022.852563","journal-title":"Front Immunol"},{"key":"13093_CR55","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1111\/ene.15009","volume":"28","author":"S Harris","year":"2021","unstructured":"Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, Southworth H, Kappos L, Cohen JA, Ozanimod Study Investigators (2021) Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: post hoc analysis of phase 3 ozanimod trials. Eur J Neurol 28:3722\u20133730. https:\/\/doi.org\/10.1111\/ene.15009","journal-title":"Eur J Neurol"},{"key":"13093_CR56","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001051","volume":"8","author":"TY Lin","year":"2021","unstructured":"Lin TY, Vitkova V, Asseyer S, Serra IM, Motamedi S, Chien C, Ditzhaus M, Papadopoulou A, Benkert P, Kuhle J, Bellmann-Strobl J, Ruprecht K, Paul F, Brandt AU, Zimmermann HG (2021) Increased serum neurofilament light and thin ganglion cell-inner plexiform layer are additive risk factors for disease activity in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 8:e1051. https:\/\/doi.org\/10.1212\/nxi.0000000000001051","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13093_CR57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/1352458519901272","volume":"27","author":"B Srpova","year":"2021","unstructured":"Srpova B, Uher T, Hrnciarova T, Barro C, Andelova M, Michalak Z, Vaneckova M, Krasensky J, Noskova L, Havrdova EK, Kuhle J, Horakova D (2021) Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. Mult Scler 27:52\u201360. https:\/\/doi.org\/10.1177\/1352458519901272","journal-title":"Mult Scler"},{"key":"13093_CR58","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3390\/medicina59050865","volume":"59","author":"M Fedi\u010dov\u00e1","year":"2023","unstructured":"Fedi\u010dov\u00e1 M, Mikula P, Gdovinov\u00e1 Z, Vitkov\u00e1 M, \u017dilka N, Hanes J, Frigov\u00e1 L, Szilasiov\u00e1 J (2023) Annual plasma neurofilament dynamics is a sensitive biomarker of disease activity in patients with multiple sclerosis. Medicina (Kaunas) 59:865. https:\/\/doi.org\/10.3390\/medicina59050865","journal-title":"Medicina (Kaunas)"},{"key":"13093_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104695","volume":"74","author":"G Bose","year":"2023","unstructured":"Bose G, Healy BC, Saxena S, Saleh F, Paul A, Barro C, Lokhande HA, Polgar-Turcsanyi M, Anderson M, Glanz BI, Guttmann CRG, Bakshi R, Weiner HL, Chitnis T (2023) Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes. Mult Scler Relat Disord 74:104695. https:\/\/doi.org\/10.1016\/j.msard.2023.104695","journal-title":"Mult Scler Relat Disord"},{"key":"13093_CR60","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jamaneurol.2019.2137","volume":"76","author":"E Cant\u00f3","year":"2019","unstructured":"Cant\u00f3 E, Barro C, Zhao C, Caillier SJ, Michalak Z, Bove R, Tomic D, Santaniello A, H\u00e4ring DA, Hollenbach J, Henry RG, Cree BAC, Kappos L, Leppert D, Hauser SL, Benkert P, Oksenberg JR, Kuhle J (2019) Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol 76:1359\u20131366. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2137","journal-title":"JAMA Neurol"},{"key":"13093_CR61","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"80","author":"S Meier","year":"2023","unstructured":"Meier S, Willemse EAJ, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L, Cagol A, Barakovic M, Galbusera R, Subramaniam S, Barro C, Abdelhak A, Thebault S, Achtnichts L, Lalive P, M\u00fcller S, Pot C, Salmen A, Disanto G, Zecca C, D\u2019Souza M, Orleth A, Khalil M, Buchmann A, Du Pasquier R, Yaldizli \u00d6, Derfuss T, Berger K, Hermesdorf M, Wiendl H, Piehl F, Battaglini M, Fischer U, Kappos L, Gobbi C, Granziera C, Bridel C, Leppert D, Maceski AM, Benkert P, Kuhle J (2023) Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol 80:287\u2013297. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5250","journal-title":"JAMA Neurol"},{"key":"13093_CR62","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.3390\/diagnostics12112571","volume":"12","author":"VE Tiu","year":"2022","unstructured":"Tiu VE, Popescu BO, Enache II, Tiu C, Terecoasa E, Panea CA (2022) Serum and CSF biomarkers predict active early cognitive decline rather than established cognitive impairment at the moment of RRMS diagnosis. Diagnostics 12:2571. https:\/\/doi.org\/10.3390\/diagnostics12112571","journal-title":"Diagnostics"},{"key":"13093_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103927","volume":"63","author":"L Masanneck","year":"2022","unstructured":"Masanneck L, Rolfes L, Regner-Nelke L, Willison A, R\u00e4uber S, Steffen F, Bittner S, Zipp F, Albrecht P, Ruck T, Hartung HP, Meuth SG, Pawlitzki M (2022) Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies. Mult Scler Relat Disord 63:103927. https:\/\/doi.org\/10.1016\/j.msard.2022.103927","journal-title":"Mult Scler Relat Disord"},{"key":"13093_CR64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/13524585221123685","volume":"28","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak A, Kuhle J, Cordano C, Oertel FC, Beaudry-Richard A, Leppert D, Benkert P, Cree BA, Hauser SL, Oksenberg JR, Green AJ (2022) Longitudinal blood NFL levels are associated with the pattern and timing of progression in multiple sclerosis. Mult Scler 28:125\u2013126. https:\/\/doi.org\/10.1177\/13524585221123685","journal-title":"Mult Scler"},{"key":"13093_CR65","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","volume":"80","author":"C Tur","year":"2023","unstructured":"Tur C, Carbonell-Mirabent P, Cobo-Calvo \u00c1, Otero-Romero S, Arrambide G, Midaglia L, Castill\u00f3 J, Vidal-Jordana \u00c1, Rodr\u00edguez-Acevedo B, Zabalza A, Gal\u00e1n I, Nos C, Salerno A, Auger C, Pareto D, Comabella M, R\u00edo J, Sastre-Garriga J, Rovira \u00c0, Tintor\u00e9 M, Montalban X (2023) Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol 80:151\u2013160. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4655","journal-title":"JAMA Neurol"},{"key":"13093_CR66","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1212\/WNL.0000000000203102","volume":"100","author":"E Alvarez","year":"2023","unstructured":"Alvarez E, Kuhle J, Kappos L, Ziemssen T, Arnold D, Cross A, Boer I, Gupta AD, Hu X, Kukkaro P, Kieseier B, Zielman R, Hauser S (2023) Long-term effect of ofatumumab treatment on serum neurofilament light chain levels and NEDA-3 status in patients with RMS results from ASCLEPIOS I\/II and ALITHIOS. Neurology 100:3208. https:\/\/doi.org\/10.1212\/WNL.0000000000203102","journal-title":"Neurology"},{"key":"13093_CR67","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1177\/13524585221094224","volume":"28","author":"A Pauwels","year":"2022","unstructured":"Pauwels A, Schependom JV, Devolder L, Remoortel AV, Nagels G, Bjerke M, D\u2019Hooghe MB (2022) Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis. Mult Scler 28:1685\u20131696. https:\/\/doi.org\/10.1177\/13524585221094224","journal-title":"Mult Scler"},{"key":"13093_CR68","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1177\/1352458520952036","volume":"27","author":"G Disanto","year":"2021","unstructured":"Disanto G, Ripellino P, Riccitelli GC, Sacco R, Scotti B, Fucili A, Pravat\u00e0 E, Kuhle J, Gobbi C, Zecca C (2021) De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis. Mult Scler 27:1230\u20131239. https:\/\/doi.org\/10.1177\/1352458520952036","journal-title":"Mult Scler"},{"key":"13093_CR69","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00109-019-01812-x","volume":"97","author":"T Sehr","year":"2019","unstructured":"Sehr T, Akg\u00fcn K, Proschmann U, Bucki R, Zendzian-Piotrowska M, Ziemssen T (2019) Early central vs. peripheral immunological and neurobiological effects of fingolimod-a longitudinal study. J Mol Med (Berl) 97:1263\u20131271. https:\/\/doi.org\/10.1007\/s00109-019-01812-x","journal-title":"J Mol Med (Berl)"},{"key":"13093_CR70","unstructured":"Bove R, Craner M, Langdon D, Sienkiewicz D, Ricart J, Ansari S, Arnould S, Boer I, Derfuss T Ofatumumab effectiveness and safety in relapsing multiple sclerosis patients with breakthrough disease on oral fumarates or fingolimod: ARTIOS interim analysis. In: The Consortium of Multiple Sclerosis Centers (CMSC) 2023 Annual Meeting; May 31-June 3, 2023; Aurora, CO, USA. Poster LB10. https:\/\/cmsc.confex.com\/cmsc\/2023\/mediafile\/Handout\/Paper9095\/CMSC%202023_Bove%20R%20et%20al_ARTIOS%20Interim%20Analysis.pdf. Accessed 03 June 2024."},{"key":"13093_CR71","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1177\/13524585231196195","volume":"29","author":"FGG Gimenez","year":"2023","unstructured":"Gimenez FGG, N\u00fa\u00f1ez LC, Bosca SC, Bordas CQ, Moran JAD, Alcal\u00e1 C, Ygual GC, Miralles FP, Rubio RG, Mart\u00ednez LV, Jimenez CL, Lluch GG, Villalba JC, Casanova B (2023) Serum neurofilament light chain is a surrogate marker of NEDA-3 in multiple sclerosis. Mult Scler 29:900\u2013900. https:\/\/doi.org\/10.1177\/13524585231196195","journal-title":"Mult Scler"},{"key":"13093_CR72","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.3390\/ijms24044067","volume":"24","author":"M Seiberl","year":"2023","unstructured":"Seiberl M, Feige J, Hilpold P, Hitzl W, Machegger L, Buchmann A, Khalil M, Trinka E, Harrer A, Wipfler P, Moser T (2023) Serum neurofilament light chain as biomarker for cladribine-treated multiple sclerosis patients in a real-world setting. Int J Mol Sci 24:4067. https:\/\/doi.org\/10.3390\/ijms24044067","journal-title":"Int J Mol Sci"},{"key":"13093_CR73","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1177\/13524585231196195","volume":"29","author":"M Wessels","year":"2023","unstructured":"Wessels M, Hogenboom L, van Lierop Z, Coerver E, Moraal B, Barkhof F, van Kempen Z, Teunissen C, Killestein J, Strijbis E (2023) Serum neurofilament light in the clinic: comparing stabilization under natalizumab with ocrelizumab. Mult Scler 29:893\u2013894. https:\/\/doi.org\/10.1177\/13524585231196195","journal-title":"Mult Scler"},{"key":"13093_CR74","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1177\/13524585221123682","volume":"28","author":"S Harris","year":"2022","unstructured":"Harris S, Vermersch P, Montalban X, Hartung HP, Kappos L, Southworth H, Sheffield JK, Silva D, Cohen JA (2022) NFL as a predictor of GdE lesions in patients with relapsing multiple sclerosis treated with ozanimod in the phase 2 RADIANCE trial. Mult Scler 28:821\u2013822. https:\/\/doi.org\/10.1177\/13524585221123682","journal-title":"Mult Scler"},{"key":"13093_CR75","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/13524585211032348","volume":"28","author":"J Kuhle","year":"2022","unstructured":"Kuhle J, Daizadeh N, Benkert P, Maceski A, Barro C, Michalak Z, Sormani MP, Godin J, Shankara S, Samad TA, Jacobs A, Chung L, R\u04e7sch N, Kaiser C, Mitchell CP, Leppert D, Havari E, Kappos L (2022) Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. Mult Scler 28:573\u2013582. https:\/\/doi.org\/10.1177\/13524585211032348","journal-title":"Mult Scler"},{"key":"13093_CR76","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1177\/13524585221126910","volume":"28","author":"J Kuhle","year":"2022","unstructured":"Kuhle J, Ait-Tihyaty M, Singh A, Turkoz I, Saad Z, Triana-Baltzer G, Burcklen M, Wong J, Linscheid P, Sidorenko T, Kappos L (2022) Serum neurofilament light chain levels show marked reduction in patients treated with ponesimod: exploratory analysis from the OPTIMUM study. Mult Scler 28:1000\u20131001. https:\/\/doi.org\/10.1177\/13524585221126910","journal-title":"Mult Scler"},{"key":"13093_CR77","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/13524585221123687","volume":"28","author":"T Stenberg","year":"2022","unstructured":"Stenberg T, Farman H, Axelsson M, Blenow K, Zetterberg H, Lycke J, Novakova L (2022) Neurofilament light chain and platelet-derived growth factor receptor beta for monitoring disease activity in relapsing-remitting multiple sclerosis: a prospective single center study. Mult Scler J 28:316\u2013317. https:\/\/doi.org\/10.1177\/13524585221123687","journal-title":"Mult Scler J"},{"key":"13093_CR78","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/13524585211044667","volume":"27","author":"K Akg\u00fcn","year":"2021","unstructured":"Akg\u00fcn K, Holzwarth F, Proschmann U, Haase R, Ziemssen T (2021) Clinical and subclinical treatment effect is associated with serum neurofilament decrease in fingolimod treated people with multiple sclerosis. Mult Scler J 27:522\u2013523. https:\/\/doi.org\/10.1177\/13524585211044667","journal-title":"Mult Scler J"},{"key":"13093_CR79","doi-asserted-by":"publisher","first-page":"e1898","DOI":"10.1212\/wnl.0000000000012752","volume":"97","author":"C Bridel","year":"2021","unstructured":"Bridel C, Leurs CE, van Lierop ZYGJ, van Kempen ZLE, Dekker I, Twaalfhoven HAM, Moraal B, Barkhof F, Uitdehaag BMJ, Killestein J, Teunissen CE (2021) Serum neurofilament light association with progression in natalizumab-treated patients with relapsing-remitting multiple sclerosis. Neurology 97:e1898\u2013e1905. https:\/\/doi.org\/10.1212\/wnl.0000000000012752","journal-title":"Neurology"},{"key":"13093_CR80","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/acn3.51471","volume":"8","author":"PA Calabresi","year":"2021","unstructured":"Calabresi PA, Kappos L, Giovannoni G, Plavina T, Koulinska I, Edwards MR, Kieseier B, de Moor C, Sotirchos ES, Fisher E, Rudick RA, Sandrock A (2021) Measuring treatment response to advance precision medicine for multiple sclerosis. Ann Clin Transl Neur 8:2166\u20132173. https:\/\/doi.org\/10.1002\/acn3.51471","journal-title":"Ann Clin Transl Neur"},{"key":"13093_CR81","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1177\/13524585211047977","volume":"27","author":"T Uher","year":"2021","unstructured":"Uher T, Havrdova EK, Benkert P, Bergsland N, Krasensky J, Srpova B, Dwyer M, Tyblova M, Meier S, Vaneckova M, Horakova D, Zivadinov R, Leppert D, Kalincik T, Kuhle J (2021) Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. Mult Scler 27:2001\u20132013. https:\/\/doi.org\/10.1177\/13524585211047977","journal-title":"Mult Scler"},{"key":"13093_CR82","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1177\/1352458520912379","volume":"27","author":"T Uher","year":"2021","unstructured":"Uher T, McComb M, Galkin S, Srpova B, Oechtering J, Barro C, Tyblova M, Bergsland N, Krasensky J, Dwyer M, Havrdova EK, Posova H, Vaneckova M, Zivadinov R, Horakova D, Kuhle J, Ramanathan M (2021) Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. Mult Scler 27:220\u2013231. https:\/\/doi.org\/10.1177\/1352458520912379","journal-title":"Mult Scler"},{"key":"13093_CR83","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1212\/WNL.96.15_supplement.2261","volume":"96","author":"T Vollmer","year":"2021","unstructured":"Vollmer T, Freedman MS, Killestein J, Nos C, Vanopdenbosch L, Buffels R, Kadner K, Kuenzel T, Kulyk I, Hartung H-P (2021) Recently diagnosed early-stage RRMS NEDA, ARR, disability progression, serum neurofilament and safety: 1-year interim data from the ocrelizumab phase IIIb ENSEMBLE study (2261). Neurology 96:2261. https:\/\/doi.org\/10.1212\/WNL.96.15_supplement.2261","journal-title":"Neurology"},{"key":"13093_CR84","doi-asserted-by":"publisher","first-page":"9299","DOI":"10.1038\/s41598-021-88624-7","volume":"11","author":"PE Walo-Delgado","year":"2021","unstructured":"Walo-Delgado PE, de la Maza SS, Villarrubia N, Monreal E, Medina S, Espi\u00f1o M, Fern\u00e1ndez-Velasco JI, Rodr\u00edguez-Mart\u00edn E, Rold\u00e1n E, Lourido D, Muriel A, Masjuan-Vallejo J, Costa-Frossard L, Villar LM (2021) Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment. Sci Rep 11:9299. https:\/\/doi.org\/10.1038\/s41598-021-88624-7","journal-title":"Sci Rep"},{"key":"13093_CR85","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1177\/1352458519882279","volume":"26","author":"G Bsteh","year":"2020","unstructured":"Bsteh G, Berek K, Hegen H, Teuchner B, Buchmann A, Voortman MM, Auer M, Wurth S, Zinganell A, Pauli FD, Deisenhammer F, Khalil M, Berger T (2020) Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis. Mult Scler 26:1682\u20131690. https:\/\/doi.org\/10.1177\/1352458519882279","journal-title":"Mult Scler"},{"key":"13093_CR86","doi-asserted-by":"publisher","first-page":"e1201","DOI":"10.1212\/wnl.0000000000009097","volume":"94","author":"B Delcoigne","year":"2020","unstructured":"Delcoigne B, Manouchehrinia A, Barro C, Benkert P, Michalak Z, Kappos L, Leppert D, Tsai JA, Plavina T, Kieseier BC, Lycke J, Alfredsson L, Kockum I, Kuhle J, Olsson T, Piehl F (2020) Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology 94:e1201\u2013e1212. https:\/\/doi.org\/10.1212\/wnl.0000000000009097","journal-title":"Neurology"},{"key":"13093_CR87","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ane.13152","volume":"141","author":"D Ferraro","year":"2020","unstructured":"Ferraro D, Guicciardi C, De Biasi S, Pinti M, Bedin R, Camera V, Vitetta F, Nasi M, Meletti S, Sola P (2020) Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients. Acta Neurol Scand 141:16\u201321. https:\/\/doi.org\/10.1111\/ane.13152","journal-title":"Acta Neurol Scand"},{"key":"13093_CR88","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/nejmoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, H\u00e4ring DA, Ramanathan K, Merschhemke M, Kappos L, Asclepios I and ASCLEPIOS II Trial Groups (2020) Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383:546\u2013557. https:\/\/doi.org\/10.1056\/nejmoa1917246","journal-title":"N Engl J Med"},{"key":"13093_CR89","doi-asserted-by":"publisher","first-page":"e2457","DOI":"10.1212\/wnl.0000000000009571","volume":"94","author":"A Manouchehrinia","year":"2020","unstructured":"Manouchehrinia A, Stridh P, Khademi M, Leppert D, Barro C, Michalak Z, Benkert P, Lycke J, Alfredsson L, Kappos L, Piehl F, Olsson T, Kuhle J, Kockum I (2020) Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology 94:e2457\u2013e2467. https:\/\/doi.org\/10.1212\/wnl.0000000000009571","journal-title":"Neurology"},{"key":"13093_CR90","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00415-020-09832-1","volume":"267","author":"F Mattioli","year":"2020","unstructured":"Mattioli F, Bellomi F, Stampatori C, Mariotto S, Ferrari S, Monaco S, Mancinelli C, Capra R (2020) Longitudinal serum neurofilament light chain (sNfL) concentration relates to cognitive function in multiple sclerosis patients. J Neurol 267:2245\u20132251. https:\/\/doi.org\/10.1007\/s00415-020-09832-1","journal-title":"J Neurol"},{"key":"13093_CR91","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/ane.13078","volume":"139","author":"P de Flon","year":"2019","unstructured":"de Flon P, Laurell K, Sundstr\u00f6m P, Blennow K, S\u00f6derstr\u00f6m L, Zetterberg H, Gunnarsson M, Svenningsson A (2019) Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. Acta Neurol Scand 139:462\u2013468. https:\/\/doi.org\/10.1111\/ane.13078","journal-title":"Acta Neurol Scand"},{"key":"13093_CR92","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000562","volume":"6","author":"AR Gafson","year":"2019","unstructured":"Gafson AR, Savva C, Thorne T, David M, Gomez-Romero M, Lewis MR, Nicholas R, Heslegrave A, Zetterberg H, Matthews PM (2019) Breaking the cycle: reversal of flux in the tricarboxylic acid cycle by dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 6:e562. https:\/\/doi.org\/10.1212\/nxi.0000000000000562","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13093_CR93","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1136\/jnnp-2019-321321","volume":"90","author":"T Sejbaek","year":"2019","unstructured":"Sejbaek T, Nielsen HH, Penner N, Plavina T, Mendoza JP, Martin NA, Elkjaer ML, Ravnborg MH, Illes Z (2019) Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients. J Neurol Neurosurg Psychiatry 90:1324\u20131330. https:\/\/doi.org\/10.1136\/jnnp-2019-321321","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13093_CR94","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acn3.638","volume":"5","author":"T Chitnis","year":"2018","unstructured":"Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, H\u00e4ring D, Leppert D, Kappos L, Bakshi R, Weiner HL, Kuhle J (2018) Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neur 5:1478\u20131491. https:\/\/doi.org\/10.1002\/acn3.638","journal-title":"Ann Clin Transl Neur"},{"key":"13093_CR95","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/acn3.51305","volume":"8","author":"K Galetta","year":"2021","unstructured":"Galetta K, Deshpande C, Healy BC, Glanz B, Ziehn M, Saxena S, Paul A, Saleh F, Collins M, Gaitan-Walsh P, Castro-Mendoza P, Weiner HL, Chitnis T (2021) Serum neurofilament levels and patient-reported outcomes in multiple sclerosis. Ann Clin Transl Neur 8:631\u2013638. https:\/\/doi.org\/10.1002\/acn3.51305","journal-title":"Ann Clin Transl Neur"},{"key":"13093_CR96","doi-asserted-by":"publisher","first-page":"e2120","DOI":"10.1212\/wnl.0000000000200258","volume":"98","author":"D Leppert","year":"2022","unstructured":"Leppert D, Kropshofer H, H\u00e4ring DA, Dahlke F, Patil A, Meinert R, Tomic D, Kappos L, Kuhle J (2022) Blood neurofilament light in progressive multiple sclerosis: post hoc analysis of 2 randomized controlled trials. Neurology 98:e2120\u2013e2131. https:\/\/doi.org\/10.1212\/wnl.0000000000200258","journal-title":"Neurology"},{"key":"13093_CR97","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200052","volume":"10","author":"C Barro","year":"2023","unstructured":"Barro C, Healy BC, Liu Y, Saxena S, Paul A, Polgar-Turcsanyi M, Guttmann CRG, Bakshi R, Kropshofer H, Weiner HL, Chitnis T (2023) Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 10:e200052. https:\/\/doi.org\/10.1212\/nxi.0000000000200052","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13093_CR98","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1177\/13524585231198396","volume":"29","author":"V Fern\u00e1ndez","year":"2023","unstructured":"Fern\u00e1ndez V, Pappolla A, Carbonell P, Tintor\u00e9 M, Rodriguez-Barranco M, Castillo M, Gutierrez L, Fissolo N, Leon-Plaza O, Ari\u00f1o H, Auger C, Bollo L, Castillo-Justribo J, Carvajal R, Calvo AC, Espejo C, Gal\u00e1n I, Guio-Sanchez C, La Puma D, Midaglia L, Mongay-Ochoa N, Nos C, Rodr\u00edguez B, Sastre-Garriga J, Tagliani P, Tur C, Vidal-Jordana A, Vilaseca A, Villacieros-Alvarez J, Zabalza A, Ca\u00f1ellas AR, Comabella M, Montalban X, Rio J, Arrambide G (2023) Serum neurofilament light chain z-scores and glial fibrillary acidic protein levels decrease at 1 year of DMT initiation, mostly under monoclonal antibodies, and said decrease could predict NEDA at 2 years in subjects with RRMS. Mult Scler 29:1063\u20131064. https:\/\/doi.org\/10.1177\/13524585231198396","journal-title":"Mult Scler"},{"key":"13093_CR99","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1177\/13524585221118676","volume":"28","author":"ZYGJ van Lierop","year":"2022","unstructured":"van Lierop ZYGJ, Noteboom S, Steenwijk MD, van Dam M, Toorop AA, van Kempen ZLE, Moraal B, Barkhof F, Uitdehaag BMJ, Schoonheim MM, Teunissen CE, Killestein J (2022) Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis. Mult Scler 28:2231\u20132242. https:\/\/doi.org\/10.1177\/13524585221118676","journal-title":"Mult Scler"},{"key":"13093_CR100","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1177\/1352458520972573","volume":"27","author":"PA Calabresi","year":"2021","unstructured":"Calabresi PA, Arnold DL, Sangurdekar D, Singh CM, Altincatal A, de Moor C, Engle B, Goyal J, Deykin A, Szak S, Kieseier BC, Rudick RA, Plavina T (2021) Temporal profile of serum neurofilament light in multiple sclerosis: implications for patient monitoring. Mult Scler 27:1497\u20131505. https:\/\/doi.org\/10.1177\/1352458520972573","journal-title":"Mult Scler"},{"key":"13093_CR101","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/13524585211047080","volume":"27","author":"R Fox","year":"2021","unstructured":"Fox R, Peelen E, Ondru\u0161 M, Muehler A (2021) Relationship between neurofilament light chain and disease activity in relapsing MS: observations from a phase II trial of IMU-838. Mult Scler 27:793. https:\/\/doi.org\/10.1177\/13524585211047080","journal-title":"Mult Scler"},{"key":"13093_CR102","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/acn3.51574","volume":"9","author":"RJ Fox","year":"2022","unstructured":"Fox RJ, Wiendl H, Wolf C, De Stefano N, Sellner J, Gryb V, Rejdak K, Bozhinov PS, Tomakh N, Skrypchenko I, Muehler AR (2022) A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis. Ann Clin Transl Neur 9:977\u2013987. https:\/\/doi.org\/10.1002\/acn3.51574","journal-title":"Ann Clin Transl Neur"},{"key":"13093_CR103","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000714","volume":"7","author":"T Uher","year":"2020","unstructured":"Uher T, Schaedelin S, Srpova B, Barro C, Bergsland N, Dwyer M, Tyblova M, Vodehnalova K, Benkert P, Oechtering J, Leppert D, Naegelin Y, Krasensky J, Vaneckova M, Havrdova EK, Kappos L, Zivadinov R, Horakova D, Kuhle J, Kalincik T (2020) Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurol Neuroimmunol Neuroinflamm 7:e714. https:\/\/doi.org\/10.1212\/nxi.0000000000000714","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13093_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103590","volume":"72","author":"T Uphaus","year":"2021","unstructured":"Uphaus T, Steffen F, Muthuraman M, Ripfel N, Fleischer V, Groppa S, Ruck T, Meuth SG, Pul R, Kleinschnitz C, Ellwardt E, Loos J, Engel S, Zipp F, Bittner S (2021) NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study. EBioMedicine 72:103590. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103590","journal-title":"EBioMedicine"},{"key":"13093_CR105","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200055","volume":"10","author":"F Steffen","year":"2023","unstructured":"Steffen F, Uphaus T, Ripfel N, Fleischer V, Schraad M, Gonzalez-Escamilla G, Engel S, Groppa S, Zipp F, Bittner S (2023) Serum neurofilament identifies patients with multiple sclerosis with severe focal axonal damage in a 6-year longitudinal cohort. Neurol Neuroimmunol Neuroinflamm 10:e200055. https:\/\/doi.org\/10.1212\/nxi.0000000000200055","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13093_CR106","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/acn3.795","volume":"6","author":"MP Sormani","year":"2019","unstructured":"Sormani MP, H\u00e4ring DA, Kropshofer H, Leppert D, Kundu U, Barro C, Kappos L, Tomic D, Kuhle J (2019) Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. Ann Clin Transl Neur 6:1081\u20131089. https:\/\/doi.org\/10.1002\/acn3.795","journal-title":"Ann Clin Transl Neur"},{"key":"13093_CR107","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/ene.15865","volume":"30","author":"JH Schaefer","year":"2023","unstructured":"Schaefer JH, Schaller-Paule MA, Wenger K, Mayer C, Mann U, Bickert A, Steffen F, Bittner S, Yalachkov Y, Foerch C (2023) Relevance of dedicated multiple sclerosis serum biomarkers in predicting contrast enhancement with gadolinium: results from the REDUCE-GAD trial. Eur J Neurol 30:2393\u20132400. https:\/\/doi.org\/10.1111\/ene.15865","journal-title":"Eur J Neurol"},{"key":"13093_CR108","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/acn3.50872","volume":"6","author":"D Jakimovski","year":"2019","unstructured":"Jakimovski D, Kuhle J, Ramanathan M, Barro C, Tomic D, Hagemeier J, Kropshofer H, Bergsland N, Leppert D, Dwyer MG, Michalak Z, Benedict RHB, Weinstock-Guttman B, Zivadinov R (2019) Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann Clin Transl Neur 6:1757\u20131770. https:\/\/doi.org\/10.1002\/acn3.50872","journal-title":"Ann Clin Transl Neur"},{"key":"13093_CR109","doi-asserted-by":"publisher","first-page":"175628641987832","DOI":"10.1177\/1756286419878324","volume":"12","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Tenenbaum N, Bhatt A, Zhang Y, Kappos L (2019) Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord 12:1756286419878324. https:\/\/doi.org\/10.1177\/1756286419878324","journal-title":"Ther Adv Neurol Disord"},{"key":"13093_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.842354","volume":"13","author":"JI Fern\u00e1ndez-Velasco","year":"2022","unstructured":"Fern\u00e1ndez-Velasco JI, Monreal E, Kuhle J, Meca-Lallana V, Meca-Lallana J, Izquierdo G, Oreja-Guevara C, Gasc\u00f3n-Gim\u00e9nez F, de la Maza SS, Walo-Delgado PE, Lapuente-Suanzes P, Maceski A, Rodr\u00edguez-Mart\u00edn E, Rold\u00e1n E, Villarrubia N, Saiz A, Blanco Y, Diaz-P\u00e9rez C, Valero-L\u00f3pez G, Diaz-Diaz J, Aladro Y, Brieva L, \u00cd\u00f1iguez C, Gonz\u00e1lez-Su\u00e1rez I, Rodr\u00edguez de Antonio LA, Garc\u00eda-Dom\u00ednguez JM, Sabin J, Llufriu S, Masjuan J, Costa-Frossard L, Villar LM (2022) Baseline inflammatory status reveals dichotomic immune mechanisms involved in primary-progressive multiple sclerosis pathology. Front Immunol 13:842354. https:\/\/doi.org\/10.3389\/fimmu.2022.842354","journal-title":"Front Immunol"},{"key":"13093_CR111","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1177\/1352458520937282","volume":"27","author":"EE Longbrake","year":"2021","unstructured":"Longbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, Chen C, Kapadia S, Mendoza JP, Miller C, Parks B, Xing D, Robertson D (2021) Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Mult Scler 27:883\u2013894. https:\/\/doi.org\/10.1177\/1352458520937282","journal-title":"Mult Scler"},{"key":"13093_CR112","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/13524585231196194","volume":"29","author":"V Maltby","year":"2023","unstructured":"Maltby V, Lea R, Xavier A, Monif M, Min M, Pedrini M, Buzzard K, Kalincik T, Kermode A, Taylor B, Hodgkinson S, Mccombe P, Osborne M, Butzkueven H, Barnett M, Leppert D, Kuhle J, Lechner-Scott J (2023) Cladribine: a multicentre, long-term efficacy and biomarker Australian study (CLOBAS)-results from the first 30 months. Mult Scler 29:572\u2013573. https:\/\/doi.org\/10.1177\/13524585231196194","journal-title":"Mult Scler"},{"key":"13093_CR113","doi-asserted-by":"publisher","first-page":"205521732211150","DOI":"10.1177\/20552173221115023","volume":"8","author":"Y Mao-Draayer","year":"2022","unstructured":"Mao-Draayer Y, Cohen JA, Bar-Or A, Han MH, Singer B, Williams IM, Meng X, Elam C, Weiss JL, Cox GM, Ziehn M, Cree BAC, FLUENT study investigators (2022) Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: the FLUENT study. Mult Scler J Exp Transl Clin 8:20552173221115024. https:\/\/doi.org\/10.1177\/20552173221115023","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"13093_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103136","volume":"54","author":"A Olsson","year":"2021","unstructured":"Olsson A, Gustavsen S, Langkilde AR, Hansen TH, Sellebjerg F, S\u00f8ndergaard HB, Oturai AB (2021) Circulating levels of tight junction proteins in multiple sclerosis: association with inflammation and disease activity before and after disease modifying therapy. Mult Scler Relat Disord 54:103136. https:\/\/doi.org\/10.1016\/j.msard.2021.103136","journal-title":"Mult Scler Relat Disord"},{"key":"13093_CR115","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/13524585231169437","volume":"29","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, De Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, J\u00e4rvinen E, Chudecka A, Gardner L (2023) Blood biomarker dynamics in highly active relapsing multiple sclerosis patients treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Mult Scler 29:21\u201322. https:\/\/doi.org\/10.1177\/13524585231169437","journal-title":"Mult Scler"},{"key":"13093_CR116","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/13524585221123687","volume":"28","author":"VF Moreira Ferreira","year":"2022","unstructured":"Moreira Ferreira VF, Zurawski J, Healy BC, Saxena S, Paul A, Saleh F, Liu Y, Polgar-Turcsanyi M, Kropshofer H, Weiner HL, Chitnis T (2022) Serum GFAP and long-term outcomes in high efficacy versus low efficacy early treatment in multiple sclerosis. Mult Scler 28:355. https:\/\/doi.org\/10.1177\/13524585221123687","journal-title":"Mult Scler"},{"key":"13093_CR117","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/13524585221094745","volume":"28","author":"S Harris","year":"2022","unstructured":"Harris S, Comi G, Cree BA, Arnold DL, Steinman L, Sheffield JK, Southworth H, Maddux R, Kappos L, Cohen JA (2022) Inverse relationship between plasma neurofilament light chain concentration and symbol digit modalities test scores in the phase 3 SUNBEAM trial of ozanimod in relapsing multiple sclerosis. Mult Scler 28:36\u201337. https:\/\/doi.org\/10.1177\/13524585221094745","journal-title":"Mult Scler"},{"key":"13093_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102534","volume":"46","author":"L Friedova","year":"2020","unstructured":"Friedova L, Motyl J, Srpova B, Oechtering J, Barro C, Vodehnalova K, Andelova M, Noskova L, Fialov\u00e1 L, Havrdova EK, Horakova D, Benedict RHB, Kuhle J, Uher T (2020) The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. Mult Scler Relat Disord 46:102534. https:\/\/doi.org\/10.1016\/j.msard.2020.102534","journal-title":"Mult Scler Relat Disord"},{"key":"13093_CR119","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1177\/13524585221123687","volume":"28","author":"C Barro","year":"2022","unstructured":"Barro C, Healy BC, Bose G, Lokhande H, Saxena S, Ferreira VFM, Polgar-Turcsanyi M, Bakshi R, Weiner HL, Chitnis T (2022) Prognostic value of neurofilament light and glial fibrillary acidic protein for disability worsening PIRA by age range in multiple sclerosis. Mult Scler 28:306\u2013306. https:\/\/doi.org\/10.1177\/13524585221123687","journal-title":"Mult Scler"},{"key":"13093_CR120","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/13524585221137697","volume":"29","author":"C Barro","year":"2023","unstructured":"Barro C, Healy BC, Saxena S, Glanz BI, Paul A, Polgar-Turcsanyi M, Guttmann CRG, Bakshi R, Weiner HL, Chitnis T (2023) Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients. Mult Scler 29:206\u2013211. https:\/\/doi.org\/10.1177\/13524585221137697","journal-title":"Mult Scler"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13093-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13093-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13093-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T09:25:28Z","timestamp":1749893128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13093-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":120,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["13093"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13093-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark S. Freedman, in the previous 2\u00a0years, received research or educational grants from Sanofi-Genzyme Canada; received honoraria or consultation fees from Alexion\/AstraZeneca, Biogen Idec, EMD Inc.\/EMD Serono\/Merck Serono, Find Therapeutics, Hoffman La-Roche, Horizon Therapeutics\/Amgen, Novartis, Sandoz, Sanofi-Genzyme, Sentrex, and Teva Canada Innovation; was a member of a company advisory board, board of directors, or other similar groups for Alexion\/AstraZeneca, Actelion\/Janssen (J&J), Atara Biotherapeutics, Bayer Healthcare, Celestra Health, EMD Inc.\/Merck Serono, Find Therapeutics, Hoffman La-Roche, Neurogenesis, Novartis, Sanofi-Genzyme, and Sentrex, Setpoint Medical; and participated in a speaker\u2019s bureau sponsored by Hoffman La-Roche, Novartis, and EMD Inc. Ahmed Abdelhak received research funding from the German Multiple Sclerosis Society, the Department of Defense, and the UCSF Weill Institute for Neurosciences. He received speaker fees from Roche and consultation fee from Octave Bio. Jason Freeman is an employee of Novartis Pharmaceuticals, USA. Sharmilee Gnanapavan had received consultation fees and grant support from Novartis, Sanofi-Genzyme, Merck and Roche, UK MS Society, NMSS, NIHR, and NHS Digital. Friedemann Paul has no conflict of interest. Sheshank Madiraju, Salman Hussain, and Mohit K. Bhutani are employees of Novartis Healthcare Private Limited, India.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"400"}}